Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Chronic Heart Failure
Interventions
DRUG

RLX030 (serelaxin)

RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.

DRUG

Placebo

Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.

Trial Locations (52)

3220

Novartis Investigative Site, Geelong

10117

Novartis Investigative Site, Berlin

11650

Novartis Investigative Site, Villamartín

13353

Novartis Investigative Site, Berlin

17475

Novartis Investigative Site, Greifswald

20521

Novartis Investigative Site, Turku

20900

Novartis Investigative Site, Monza

23562

Novartis Investigative Site, Lübeck

24105

Novartis Investigative Site, Kiel

25123

Novartis Investigative Site, Brescia

26480

Novartis Investigative Site, Meselik / Eskisehir

28007

Novartis Investigative Site, Madrid

28040

Novartis Investigative Site, Madrid

29010

Novartis Investigative Site, Málaga

30159

Novartis Investigative Site, Hanover

32216

Novartis Investigative Site, Jacksonville

33143

Novartis Investigative Site, South Miami

34668

Novartis Investigative Site, Haydarpasa/Istanbul

37920

Novartis Investigative Site, Knoxville

39112

Novartis Investigative Site, Magdeburg

41014

Novartis Investigative Site, Seville

41380

Novartis Investigative Site, Kocaeli

52044

Novartis Investigative Site, Cortona

55404

Novartis Investigative Site, Minneapolis

55417

Novartis Investigative Site, Minneapolis

58140

Novartis Investigative Site, Sivas

60488

Novartis Investigative Site, Frankfurt

80918

Novartis Investigative Site, Colorado Springs

92801

Novartis Investigative Site, Anaheim

109469

Novartis Investigative Site, Moscow

117198

Novartis Investigative Site, Moscow

200059

Novartis Investigative Site, Vimercate

200642

Novartis Investigative Site, Craiova

540136

Novartis Investigative Site, Târgu Mureş

550245

Novartis Investigative Site, Sibiu

27599-7075

Novartis Investigative Site, Chapel Hill

23298-0050

Novartis Investigative Site, Richmond

VIC 3004

Novartis Investigative Site, Melbourne

625 00

Novartis Investigative Site, Brno - Bohunice

586 01

Novartis Investigative Site, Jihlava

128 08

Novartis Investigative Site, Prague

01069

Novartis Investigative Site, Dresden

D-67269

Novartis Investigative Site, Grünstadt

07740

Novartis Investigative Site, Jena

8601 ZR

Novartis Investigative Site, Sneek

Unknown

Novartis Investigative Site, Groningen

3000 CA

Novartis Investigative Site, Rotterdam

0424

Novartis Investigative Site, Oslo

014461

Novartis Investigative Site, Bucharest

021659

Novartis Investigative Site, Bucharest

141 86

Novartis Investigative Site, Stockholm

06110

Novartis Investigative Site, Diskapi / Ankara

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY